Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice
暂无分享,去创建一个
S. Slager | S. Achenbach | N. Kay | Yucai Wang | K. Rabe | S. Hayman | N. Leung | Eli Muchtar | T. Call | S. Parikh | S. Kenderian | J. Leis | W. Ding | S. Schwager | H. Finnes | P. Hampel | A. Koehler
[1] D. Stephens. Venetoclax and Obinutuzumab for Front-line Treatment of Chronic Lymphocytic Leukemia. , 2019, Blood.
[2] S. Slager,et al. BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression , 2019, Blood.
[3] T. Kipps,et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. , 2019, The New England journal of medicine.
[4] S. Slager,et al. PS1162 COMBINATION THERAPY TO PREVENT IBRUTINIB WITHDRAWAL: CONTINUED IBRUTINIB WITH THE ADDITION OF VENETOCLAX AT TIME OF PROGRESSION IN IBRUTINIB-TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) , 2019, HemaSphere.
[5] Naveen Garg,et al. Ibrutinib and Venetoclax for First-Line Treatment of CLL. , 2019, The New England journal of medicine.
[6] T. Shanafelt,et al. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice , 2019, Leukemia & lymphoma.
[7] B. Cheson,et al. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice , 2019, Clinical Cancer Research.
[8] J. Byrd,et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. , 2018, Blood.
[9] Jeffrey A Jones,et al. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia , 2018, Clinical Cancer Research.
[10] A. Zelenetz,et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States , 2018, Haematologica.
[11] Marco Montillo,et al. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia , 2018, The New England journal of medicine.
[12] P. Westervelt,et al. Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies , 2012, Journal of Hematology & Oncology.
[13] C. Pui,et al. The tumor lysis syndrome. , 2011, The New England journal of medicine.
[14] M. Cairo,et al. Tumour lysis syndrome: new therapeutic strategies and classification , 2004, British journal of haematology.
[15] K. Hande,et al. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. , 1993, The American journal of medicine.